Cancer Family
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
CI-CAN-00000175Explore in graph →
Non-malignant81 active trials1 approved drugs18 evidence items
- NCIt
- C27291
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000175Explore in graph →
Regulatory
20 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Entrectinib | EU EMA | Tumor-agnosticLung Non-Small Cell Carcinoma | Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor who have no satisfactory treatment options. Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1 positive, advanced non small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.conditional | approved | Jul 31, 2020 | ema |
| Larotrectinib | EU EMA | Tumor-agnostic | Vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.conditional | approved | Sep 19, 2019 | ema |
| Repotrectinib | EU EMA | Tumor-agnosticLung Non-Small Cell Carcinoma | Augtyro as monotherapy is indicated for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC). Augtyro as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with advanced solid tumours expressing a NTRK gene fusion, and who have received a prior NTRK inhibitor, or have not received a prior NTRK inhibitor and treatment options not targeting NTRK provide limited clinical benefit, or have been exhausted (see sections 4.4 and 5.1) |
Data updated 8 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Pazopanib | 3 | 3 | 0 |
| IGF1R Monoclonal Antibody | 2 | 2 | 0 |
| Linsitinib | 2 | 2 | 0 |
| Palbociclib | 2 | 2 | 0 |
| Ponatinib | 2 | 2 | 0 |
| Temsirolimus | 2 | 2 | 0 |
| Cixutumumab | 1 | 1 | 0 |
| Conatumumab | 1 | 1 | 0 |
| Elimusertib | 1 | 1 | 0 |
| HCI-2509 | 1 | 1 | 0 |
| Niraparib | 1 | 1 | 0 |
| Temozolomide | 1 | 1 | 0 |
| Teprotumumab |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| approved |
| Jan 13, 2025 |
| ema |
| Selpercatinib | EU EMA | Tumor-agnostic | Retsevmo as monotherapy is indicated for the treatment of adults with: advanced RET fusion positive non small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. For biomarker-based patient selection, see section 4.2. Retsevmo as monotherapy is indicated for the treatment of adults and paediatric patients 2 years of age and older with: advanced RET fusion positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate) . For biomarker-based patient selection, see section 4.2. advanced RET mutant medullary thyroid cancer (MTC) . For biomarker-based patient selection, see section 4.2. advanced RET fusion positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted (see sections 4.4 and 5.1). For biomarker-based patient selection, see section 4.2. | approved | Feb 11, 2021 | ema |
| 1 |
| 1 |
| 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.